CJC 1295 W DAC (2mg)0 out of 5(0)
CJC-1295 is a synthetic analog of the Growth Hormone-Releasing Hormone. With a substitution of four amino acids, it is more resistant to proteolytic inactivation by dipeptidyl peptidase IV (DPP-IV). When combined with Drug Affinity Complex (DAC), it prolongs its half-life, as well as the duration of action in test subjects.
Studies in animals (rats, pigs, and dogs) show that serum IGF-I levels increase several days after a single administration of CJC-1295 with DAC. It sustained a dose-dependent stimulation of serum GH and IGF-I levels when injected into healthy subjects at intervals of 1-2 weeks.
It increases plasma levels of growth hormone from somatotropic cells in the pituitary gland of animal test subjects, without altering its pulsation. It doesn’t inhibit the effects of somatostatin.$97.00
AOD9604 (5mg)0 out of 5(0)
Growth Hormone peptide Fragment 176-191 is also known as HGH Frag 176-191 and AOD9604. It is the modified form of the tail end of the Human Growth Hormone (HGH) molecule, known as the C terminal region. It constitutes less than ten percent of the total size of the HGH molecule, which is the fat-reducing part. It doesn’t affect growth or insulin resistance.
It mimics the way natural Growth Hormone regulates fat metabolism but is 12.5 times stronger for weight loss. It does this without affecting blood sugar or growth observed with unmodified Growth Hormone in animal test subjects. Fragment 176-191 has been shown in studies to release fat specifically from obese fat cells but not from lean ones, reduces new fat accumulation in all fat cells, and enhances fat burning.
It has a short half-life with peak concentrations occurring around 15 minutes and no longer than 60 minutes after administration.$97.00
GHRP6 (5mg)0 out of 5(0)
ABOUT GHRP-6: It belongs in the family of the Growth Hormone secretagogue, meaning that it causes the secretion of growth hormone. It is a synthetic hexapeptide and a met-enkephalin derivative that contains a chain of 6 unnatural D amino acids.
It has no structural similarity with Growth Hormone Releasing Hormone (GHRH) and works by utilizing specific receptors present in cell cultures of the animal pituitary gland or hypothalamus.
GHRP-6 has cytoprotective effects that are non-growth Hormone-related which include neuroprotective, cardioprotective, anti-inflammatory as well as hepatoprotective effects.
Studies in animal test subjects show that GHRP-6 stimulates Ghrelin, “the hunger hormone” through its ghrelin receptor, which in turn signals an increased production of growth hormone (GH) by acting at the level of the pituitary or hypothalamus through a specific receptor different from that of the endogenous Growth Hormone-Releasing Hormone GHRH.
The four parts of the animal test subjects that demonstrate the role of GHRP-6 include the pituitary gland, central nervous system, liver, and stomach.$87.00